Cipher Pharmaceuticals (TSE:CPH) Trading Up 24.9%

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) traded up 24.9% on Monday . The stock traded as high as C$10.95 and last traded at C$10.84. 106,740 shares traded hands during trading, an increase of 232% from the average session volume of 32,118 shares. The stock had previously closed at C$8.68.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus downgraded shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating and upped their price target for the company from C$8.00 to C$9.50 in a report on Monday, May 13th.

Cipher Pharmaceuticals Trading Up 28.1 %

The company has a current ratio of 7.96, a quick ratio of 2.67 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of C$268.10 million, a P/E ratio of 8.54 and a beta of 1.05. The company has a 50-day moving average price of C$8.59 and a 200 day moving average price of C$8.00.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its quarterly earnings data on Thursday, May 9th. The company reported C$0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C$0.14 by C$0.13. Cipher Pharmaceuticals had a net margin of 102.43% and a return on equity of 29.70%. The firm had revenue of C$7.91 million for the quarter, compared to the consensus estimate of C$7.04 million. On average, research analysts forecast that Cipher Pharmaceuticals Inc. will post 0.74 earnings per share for the current fiscal year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.